無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

静脈血栓塞栓症治療市場:タイプ(深部静脈血栓症、肺塞栓症)、治療、地域別の予測

Venous Thromboembolism Treatment Market: By Type (Deep Venous Thrombosis, and Pulmonary Embolism); By Treatment (Heparin, Apixaban, Dabigatran, Rivaroxaban, Edaxaban, Others) & By Region (Europe, North America, Asia-Pacific, RoW)-Forecast (2016-2022)

発行 IndustryARC 商品コード 422791
出版日 ページ情報 英文 147 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
静脈血栓塞栓症治療市場:タイプ(深部静脈血栓症、肺塞栓症)、治療、地域別の予測 Venous Thromboembolism Treatment Market: By Type (Deep Venous Thrombosis, and Pulmonary Embolism); By Treatment (Heparin, Apixaban, Dabigatran, Rivaroxaban, Edaxaban, Others) & By Region (Europe, North America, Asia-Pacific, RoW)-Forecast (2016-2022)
出版日: 2016年09月27日 ページ情報: 英文 147 Pages
概要

当レポートでは、世界の静脈血栓塞栓症治療市場について調査し、市場の動向と戦略的分析、タイプ別、治療別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 静脈血栓塞栓症治療市場:概要

第2章 エグゼクティブサマリー

第3章 市場環境

  • 市場シェア分析
  • 競合分析
  • 製品ベンチマーキング
  • エンドユーザープロファイリング
  • 上位5社の財務分析

第4章 市場の力

  • 促進因子
  • 阻害因子
  • 機会
  • 課題
  • ポーターズファイブフォース分析

第5章 戦略的分析

  • バリューチェン分析
  • 価格分析
  • 機会分析
  • 製品/市場ライフサイクル分析
  • 供給者と販売業者

第6章 タイプ別

  • 深部静脈血栓症
  • 肺塞栓症

第7章 治療別

  • Heparin
  • Apixaban
  • Dabigatran
  • Rivaroxaban
  • Edaxaban
  • Warfarin
  • 圧迫治療
  • 下大静脈フィルター
  • 血栓溶解療法

第8章 地域別市場

  • 欧州
  • アジア太平洋地域
  • 北米
  • その他

第9章 エントロピー

  • 拡大
  • 技術的発展
  • 合併・買収、合弁
  • 供給 - 契約

第10章 企業プロファイル

第11章 付録

目次

Venous Thromboembolism (VTE) is a lethal disorder that affects the hospitalized and non-hospitalized patients, recurs frequently, and results in long-term complications including chronic thromboembolic pulmonary hypertension (CTPH) and the post-thrombotic syndrome (PTS). It includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). Globally, development of efficient and advanced technology, rise in the awareness among people regarding existing treatments for venous thromboembolism, increasing government initiatives across the globe, growing prevalence and incidence rate of venous thromboembolism are the prime growth drivers of the venous thromboembolism treatment market. In addition, an increase in adoption of venous thromboembolism treatment in emerging economies such as China, India and others, will create new opportunities for the venous thromboembolism treatment market. However, higher cost of the research and development, and complex government regulatory approvals are the key restraints for the venous thromboembolism treatment market.

Geographically, North America dominated the venous thromboembolism treatment market, because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have the fastest growth, owing to a rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the types, deep vein thrombosis (DVT) has the highest market share in the venous thromboembolism treatment market.

This report identifies the venous thromboembolism treatment market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the venous thromboembolism treatment market.

This report segments the venous thromboembolism treatment market on the basis of type, treatment, and regional market as follows:

Venous Thromboembolism Treatment Market, By Type: Deep Venous Thrombosis, and Pulmonary Embolism

The report has focused study on venous thromboembolism treatment market by basis of treatment such as: Heparin, Apixaban, Dabigatran, Rivaroxaban, Edaxaban, Warfarin, Compression Therapy, Inferior Vena Cava Filter, and Thrombolytic Therapy

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the venous thromboembolism treatment market. Some of the major companies' profiles in detail are as follows:

Abbott Laboratories

Bio Compression Systems, Inc.

Boehringer Ingelheim GmbH

Upsher-Smith Laboratories,Inc

Bristol-Myers Squibb Company

Table of Contents

1. Venous Thromboembolism Treatment Market - Overview

2. Executive Summary

3. Venous Thromboembolism Treatment Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Venous Thromboembolism Treatment Market- Forces

  • 4.1. Drivers
    • 4.1.1. Development of efficient and advance technology
    • 4.1.2. Growing prevalence and incidence rate of venous thromboembolism
  • 4.2. Restraints
    • 4.2.1. Higher cost of research and development
  • 4.3. Opportunities
    • 4.3.1. Emerging economies
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Venous Thromboembolism Treatment Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Venous Thromboembolism Treatment Market, By Type

  • 6.1. Deep Venous Thrombosis
  • 6.2. Pulmonary Embolism

7. Venous Thromboembolism Treatment Market, By Treatment

  • 7.1. Heparin
  • 7.2. Apixaban
  • 7.3. Dabigatran
  • 7.4. Rivaroxaban
  • 7.5. Edaxaban
  • 7.6. Warfarin
  • 7.7. Compression Therapy
  • 7.8. Inferior Vena Cava Filter
  • 7.9. Thrombolytic Therapy

8. Venous Thromboembolism Treatment Market, By Geography

  • 8.1. Europe
    • 8.1.1. Germany
    • 8.1.2. France
    • 8.1.3. Italy
    • 8.1.4. Spain
    • 8.1.5. Russia
    • 8.1.6. U.K.
    • 8.1.7. Rest of Europe
  • 8.2. Asia Pacific
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. South Korea
    • 8.2.5. Rest of Asia-Pacific
  • 8.3. North America
    • 8.3.1. U.S.
    • 8.3.2. Canada
    • 8.3.3. Mexico
  • 8.4. Rest of the World (RoW)
    • 8.4.1. Brazil
    • 8.4.2. Rest of RoW

9. Venous Thromboembolism Treatment - Entropy

  • 9.1. Expansion
  • 9.2. Technological Developments
  • 9.3. Merger & Acquisitions, and Joint Ventures
  • 9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 10.1. Abbott Laboratories
  • 10.2. Bio Compression Systems, Inc.
  • 10.3. Boehringer Ingelheim GmbH
  • 10.4. Upsher-Smith Laboratories,Inc
  • 10.5. Bristol-Myers Squibb Company
  • 10.6. Merck & Co.
  • 10.7. Dupont Pharm Co
  • 10.8. Wockhardt Ltd
  • 10.9. Bayer AG
  • 10.10. Pfizer Inc.

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Bibliography
  • 11.5. Compilation of Expert Insights
  • 11.6. Disclaimer
Back to Top